Back |
home / stock / heb / heb message board
Subject | By | Source | When |
---|---|---|---|
* * $HEB Video Chart 05-02-2019 * * | ClayTrader | investorshub | 05/02/2019 8:41:54 PM |
sinking fast here | Golden Cross | investorshub | 05/02/2019 2:17:42 PM |
price of warrants reduced to .15 bearish | nokomis | investorshub | 05/02/2019 2:14:17 PM |
This pure CRAP is now below the good | pberger | investorshub | 05/02/2019 1:53:20 PM |
Nasty... Looking to buy back in on a | Golden Cross | investorshub | 05/02/2019 1:09:15 PM |
* * $HEB Video Chart 05-01-2019 * * | ClayTrader | investorshub | 05/01/2019 8:57:00 PM |
Nice news today! | Golden Cross | investorshub | 05/01/2019 1:48:46 PM |
Dilution pure.... | Zarate69 | investorshub | 05/01/2019 1:48:28 PM |
Where are all these shares coming from? It | tknuncle | investorshub | 05/01/2019 1:42:45 PM |
Where is the news? Thanks | aidytrader | investorshub | 05/01/2019 1:23:21 PM |
$heb..huge news out today..shorts scrambling premarket... | TommyBoyTrader9460 | investorshub | 05/01/2019 1:13:11 PM |
26s!! | JJGl | investorshub | 05/01/2019 12:58:03 PM |
News, Short Squeeze, Breakout and More Instantly...
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...